Patupilone (EPO906, Epothilone B)

Catalog No.S1364

Patupilone (EPO906, Epothilone B) Chemical Structure

Molecular Weight(MW): 507.68

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
In DMSO USD 250 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell NFixVJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1P2cmlvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzenLUC2JO69VQ>? MmHMV2FPT0WU
human A431 cell Ml70S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUD1PXoxUW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PmVvME[g{txO NXq3foJwW0GQR1XS
human SW1710 cell NGT3eGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIj1cZdKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTSnLUC1JO69VQ>? MlywV2FPT0WU
human Daoy cell NHe0bI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfTPWk4UW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? NUS4TGxwW0GQR1XS
human BFTC-905 cell NFLaS4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46QWVvMEWg{txO MkKyV2FPT0WU
human A375 cell MlLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFHy[lFKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21[U0xPSEQvF2= M4Oz[3NCVkeHUh?=
human RKO cell M3\uRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYnVfY5wUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ4\S1yNTFOwG0> M4DScXNCVkeHUh?=
human KYSE-510 cell M1Pwcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{QGVvMEWg{txO MnLCV2FPT0WU
human HLE cell Ml3CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXPnN4l6UW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3\S1yNTFOwG0> NVu4RYQ1W0GQR1XS
human MCF7 cell M4\XPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHn2eHVKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> NUXoWJR4W0GQR1XS
human 786-0 cell NYKyR5dVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmfsTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEhdk1? MmXEV2FPT0WU
human TE-8 cell MnTFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NW\IOXd[UW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTFibl2= NEXX[5ZUSU6JRWK=
ovarian carcinoma 1A9 cell NHHnd4hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCxdnHybYFvKGOjcnPpco9u[SBzQUmgZ4VtdCCpcn;3eIg> M3[3e|E3OTN2OUK4
human PANC-03-27 cell M4LLfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MknaTY5pcWKrdHnvckBw\iCqdX3hckBRSU6FLUCzMVI4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{Kg{txO NHrOOI5USU6JRWK=
human VMRC-RCZ cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUH1VZp4UW6qaXLpeIlwdiCxZjDoeY1idiCYTWLDMXJEYiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUO2JO69VQ>? NUXpblQ6W0GQR1XS
human IGROV-1 cell NYPFb4RFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWK4UG1lUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNU[g{txO MVvTRW5ITVJ?
human MG-63 cell NFP6bnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvvS|lKdmirYnn0bY9vKG:oIHj1cYFvKE2JLU[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPjVizszN NI[yNZJUSU6JRWK=
human SIG-M5 cell M{HYbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVY6KM7:TR?= Mn3UV2FPT0WU
human NCI-H650 cell NVjGfINET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPyEQvF2= NULPSmV7W0GQR1XS
human PSN1 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fveWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc{KM7:TR?= MV\TRW5ITVJ?
human PA-1 cell Mke2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG3OEDPxE1? NXfFfIZwW0GQR1XS
KB-8511 cells NFTUdG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nQTVczKGh? Mn;xR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2{ZYPpd5RidnRiaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvOEWxNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\SluIFnDOVA:OC5zODFOwG0> M4PE[|EyOTN|MEi2
KB-31 cells NGLSfFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXi3NkBp M{O4UmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDD0bIUh\3Kxd4ToJI9nKHCjY3zpeIF5\Wxvc3Xud4l1cX[nIHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIx{KEuELUOxJIJ6KDVyIIDldoNmdnRiKEeyJIhzKGW6cH;zeZJmMQ>? MlLhNVEyOzNyOE[=
human BHY cell NFXXc45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF3FRmFKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk2KG6P M16wd3NCVkeHUh?=
human BB30-HNC cell Mn:5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYThVZNPUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkCxJO69VQ>? MXLTRW5ITVJ?
human HOS cell M4DXWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn7sTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKxOUDPxE1? M1v0U3NCVkeHUh?=
human 639-V cell NF7NOIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWjJcohq[mm2aX;uJI9nKGi3bXHuJFY{QS2YIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVgh|ryP NXvMWJhNW0GQR1XS
human ES1 cell  MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlfDTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyNUDPxE1? M1j5bnNCVkeHUh?=
human TE-15 cell  NIrYVIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUD1W|Y3UW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjJ3IN88US=> M4nP[HNCVkeHUh?=
human LXF-289 cell NWLBZ5JDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnrBTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzdizszN NXrJdHBsW0GQR1XS
human CAL-12T cell NFfGeWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2DBcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUGyWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7IN88US=> NX;YXGpsW0GQR1XS
human T84 cell NE\NXmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1vJR2lvcGmkaYTpc44hd2ZiaIXtZY4hXDh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOEDPxE1? NVXQe4dpW0GQR1XS
human KYSE-450 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2SwVmlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT20OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ4NzFOwG0> NITOS4tUSU6JRWK=
human LCLC-103H cell M2XMNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2TLfWlvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz2xNFNJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MTDuUS=> NIH5S5FUSU6JRWK=
human NCI-H810 cell NHLjRZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlPlTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{IN88US=> MV7TRW5ITVJ?
human HUTU-80 cell Mn\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\ucmlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> NV;3dpNXW0GQR1XS
human NCI-H460 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnfZTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN|IN88US=> NHrEbZhUSU6JRWK=
human HGC-27 cell MmjRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXi5XHJbUW6qaXLpeIlwdiCxZjDoeY1idiCKR1OtNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|ODFOwG0> NUTHdGxJW0GQR1XS
human HSC-2 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2TwTGlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3OyCwTR?= M{HMZ3NCVkeHUh?=
human IA-LM cell NVzs[YJrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIj1TnBKdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTNizszN MV\TRW5ITVJ?
human HMV-II cell M3;tN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k1KM7:TR?= MWXTRW5ITVJ?
human COLO-679 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1fUfGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7NDFOwG0> MnS1V2FPT0WU
human NCI-H2122 cell NXzR[IF3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3nmO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0> NVm3PI1HW0GQR1XS
human CAL-39 cell NXmxPWVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1joeWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTFizszN M{\WfHNCVkeHUh?=
human SW954 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEnZOoZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OzZizszN MUDTRW5ITVJ?
human LCLC-97TM1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIezcI1KdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtPVdVVTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS0OEDPxE1? MVnTRW5ITVJ?
human KYSE-270 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\qU4VKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNlcxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NEWg{txO NXvMeHhUW0GQR1XS
human NB13 cell M2XQdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\VXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFQ4KM7:TR?= NUT1TJE2W0GQR1XS
human SK-LMS-1 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvDTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OTWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR4IN88US=> MWnTRW5ITVJ?
human SW620 cell NXXxNIFlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2jibGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY1QCEQvF2= MlXyV2FPT0WU
human HCT-15 cell NF\MN4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnSwTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcyPyEQvF2= MYXTRW5ITVJ?
human DU-145 cell M2DPXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXz6PY5YUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd{MTFOwG0> Mm\lV2FPT0WU
human ST486 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;wSGlvcGmkaYTpc44hd2ZiaIXtZY4hW1R2OE[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= M{fUcnNCVkeHUh?=
human A427 cell NG\a[YRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{LHZ2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFI5KM7:TR?= NGLYWG9USU6JRWK=
human HT-1080 cell M3jDWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHqTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PDJizszN M2\sNnNCVkeHUh?=
human NCI-H2009 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1ywNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFA6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NkKg{txO MWDTRW5ITVJ?
human SK-LU-1 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3PiEQvF2= NWHa[m5vW0GQR1XS
human SCC-4 cell MkfVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH22eJRKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PzdizszN NXnZV|NEW0GQR1XS
human NCI-H1299 cell M{jVTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETxenpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEig{txO NYn2T25XW0GQR1XS
human NH-12 cell NIDNfpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlu2TY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFkyKM7:TR?= M3Tlb3NCVkeHUh?=
human SK-UT-1 cell NYfHV|RzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6OiEQvF2= NXjPRoNJW0GQR1XS
human Bel7402 NUOzU3d[WHKxbHnm[ZJifGmxbjDhd5NigQ>? M1zYc|czKGh? MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKnbEe0NFIh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUC9NE46KM7:TR?= NFPBcYgzOjN{MEO1OC=>
human A388 cell NETHWJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHrDZ3hKdmirYnn0bY9vKG:oIHj1cYFvKEF|OEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk1KM7:TR?= M1n5eHNCVkeHUh?=
human SW982 cell NUjEOXE6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfyTHdnUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTl7IN88US=> NHP5VHdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
+ Expand

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
+ Expand
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Formulation: Dissolved in30% PEG-300
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) supplier | purchase Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) cost | Patupilone (EPO906, Epothilone B) manufacturer | order Patupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID